one of martin shkreli's old picks (aka pharma bro)
looks like it could be breaking up here look at the CS bo the cloud with volume and fisher support
manage your risk
gl hf
xoxo
snoop
12.5.2016- $KBIO currently trading at 4.25. Potential once they receive PRV (Priority Review Voucher) for Benznidazole possibility for trading at $5-6. Stock jumped about $1 due to the Letter to Stakeholders by Dr. Cameron Durrant. I expect this stock to rise.
Disclosure: I am long $KBIO
SEE MORE: globenewswire.com
